pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›milvexian
drug · small molecule
save

milvexian

Phase 3updated 6mo ago
by Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3
community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.

indications

indications
Atrial Fibrillation

targets

Coagulation factor XI

all catalysts(0)

nothing on the calendar yet

Trials studying milvexian

  • phase3A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKEactive not recruitingn=12,532
  • phase3A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillationactive not recruitingn=20,284
  • phase3A Study of Milvexian in Participants After a Recent Acute Coronary Syndromecompletedn=14,194
  • phase1A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participantscompletedn=52
  • phase1A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participantscompletedn=115
  • phase1A Study of Milvexian in Healthy Adult Femalescompletedn=20
  • phase1A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participantscompletedn=23

News(10)

  • Deep dive: Cardiovascular calamities and catalysts
    BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
    biospace · 4d ago
  • BMS R&D head to depart amid restructure
    Bristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.
    biospace · 4d ago
  • Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
    Bayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.
    biospace · 6d ago
  • Bayer wins FDA nod for a new kind of blood thinner
    Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
    biopharma_dive · 7d ago
  • BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
    In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…
    biospace · 18d ago
  • J&J earnings set ‘negative tone’; Shkreli vs. the FTC
    A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.
    biopharma_dive · 1mo ago
  • BMS’ Phase 3 win for lung drug clouded by high-dose miss
    A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…
    biospace · 1mo ago
  • BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
    Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.
    fiercebiotech · 1mo ago
  • BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
    BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for…
    biospace · 1mo ago
  • BMS reports liver injury events in lung disease program, with key readout near
    Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…
    biospace · 1mo ago
view all news mentions →
generic
milvexian
MOA
Coagulation factor XI inhibitor
indication
Acute Ischemic Stroke
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?